Articles by : Rich Daly, Editor in Chief

Contract Pharmacies Have Proliferated, Conservative Group Says, Citing Data from Pharma-Funded Think Tank

April 4, 2024 Rich Daly, Editor in Chief Views

A Paragon Health Institute analysis found the share of 340B contract pharmacies per covered entity has increased in recent years.

Active 340B contract pharmacies reached 17,250 in 2024, according to a conservative think tank using data collected by another group funded by [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Sumitomo Is Thirty-Second Company to Implement Contract Pharmacy Restrictions

April 2, 2024 Rich Daly, Editor in Chief Views

Sumitomo is the 32nd pharmaceutical manufacturer to place restrictions on 340B drug shipment in the contract pharmacy setting.

Drugmaker Sumitomo Pharma America (SMPA) announced it will implement first-time contract pharmacy restrictions next month. The biotech company, which is [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Amgen, J&J to Issue Refunds on High-Selling Drugs to 340B Providers

April 2, 2024 Rich Daly, Editor in Chief Views

Drugmakers Amgen and Johnson & Johnson have announced they will provide refunds to 340B providers on past purchases of multiple [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Estimated 340B Revenue Exceeded Charity Care Spending for 85% of DSH Hospitals, Says Pharma-backed Group

April 2, 2024 Rich Daly, Editor in Chief Views

340B revenue exceeds charity care spending for most DSH hospitals, said a report from drug industry-backed AIR340B.

Eighty-five percent of DSH hospitals earned more in estimated 340B revenue in 2022 than they incurred in charity care costs, [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Three 340B Terminations, Seven Paybacks to Manufacturers in Latest Provider Audit Findings

March 28, 2024 Rich Daly, Editor in Chief Views

Federal regulators released a March 20 update to ongoing 340B program integrity audits for fiscal year 2023.

Federal auditors determined terminations from the 340B program were required for either a covered entity site or a contract pharmacy [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Judge Dismisses Health System’s Penny Pricing Coordination Lawsuit Against Drugmakers

March 26, 2024 Rich Daly, Editor in Chief Views

A federal district judge has dismissed Calif.-based Adventist West's lawsuit against four drug manufacturers.

A federal judge recently dismissed a large California health system’s whistleblower case against four pharmaceutical companies for alleged fraudulent 340B [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Senate, House Appropriators Agree on Budget for Office of Pharmacy Affairs but Have Different Priorities

March 21, 2024 Rich Daly, Editor in Chief Views

Senate and House appropriators have agreed on funding for HHS and the office within it that oversees 340B, but they appear to have different regulatory priorities.

While it appears that Senate and House appropriators have agreed on a funding level for the office that oversees the [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

California Ballot Initiative Targets Big 340B Provider Serving HIV Population

March 21, 2024 Rich Daly, Editor in Chief Views

Tom Myers, general counsel for AHF, said a California ballot measure is intended as retaliation against the HIV/AIDS group.

A California ballot initiative aims to codify the California governor’s 2019 shift of the Medicaid program’s prescription drug benefit from [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Hospitals’ Low-Income Prostate Cancer Patients Had Better Adherence

March 19, 2024 Rich Daly, Editor in Chief Views

Dr. Kassem Faraj and his co-authors at the University of Michigan found 340B was associated with better treatment adherence for more vulnerable prostate cancer patients.

Although 340B participation did not correlate to the start of costly treatment for men with advanced prostate cancer enrolled in [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

340B Small Share of Drugmaker Revenue, Says Hospital-Backed Report

March 14, 2024 Rich Daly, Editor in Chief Views

340B drug discounts only amounted to a small percentage of total drugmaker revenue, a hospital-funded study found.

Despite the increase in the amount of 340B program drug discounts, those only amounted to 3.1% of global and 7% [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a

…

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Please Login or Become a Paid Subscriber to View this Content

If you are already a

Site Footer Live